News
-
Herantis Pharma has signed an agreement with nanoparticle technology company Nanoform Finland to try out Nanoform’s biologics nanoparticle technology for intranasal formulations of CDNF (cerebral dopamine neurotrophic factor). Nanoform launched its nanoparticle technology for biologics… Read more . . .
-
Hovione Technology, a subsidiary of CDMO Hovione, announced that it has been granted a patent on a new method of particle size analysis that provides improved sample preparation for more accurate measurements and better repeatability.… Read more . . .
-
According to Janssen, the company’s Spravato esketamine nasal spray has been approved by the EC as an add-on to oral antidepressants for adult patients with major depressive disorder (MDD) “as acute short term treatment, for… Read more . . .
-
NeuroRx announced that it has initiated a Phase 2/3 clinical trial of nebulized Zyesami aviptadil (RLF-100) for the treatment of severe COVID-19. In August 2020, NeuroRx announced that the FDA had cleared an IND for… Read more . . .
-
AuraVax Therapeutics, which is developing an intranasal vaccine against COVID-19, announced that it has acquired an exclusive license for IP related to intranasal respiratory vaccine technology and STING agonist technology from the University of Houston. Earlier… Read more . . .
-
Lindal Group announced that the Chinese National Medical Product Administration’s (NMPA) Center for Drug Evaluation (CDE) has listed the drug master file (DMF) for Lindal’s 20 mm male MDI metering valve as active following review.… Read more . . .
-
Aptar Pharma subsidiary Noble has launched a suite of services for makers of combination products such as OINDPs under the “Human Factors Plus” (HF+) brand. Noble, which was acquired by Aptar Pharma in 2019, makes… Read more . . .
-
The European Commission has approved Chiesi’s Trimbow extrafine beclometasone / formoterol / glycopyrronium MDI for the treatment of asthma in patients who do not have adequate control with ICS/LABA and who have had at least… Read more . . .
-
Verona Pharma reported that a Phase 2 study of 3 dose levels of its MDI formulation of ensifentrine in patients with moderate to severe COPD met all of its primary and secondary endpoints, demonstrating significant… Read more . . .
-
Revelation Biosciences said that it has closed a private placement financing with gross proceeds of $4.4 million that it plans to use for development of two pipeline products, including its REVTx-99 intranasal phosphorylated hexaacylated disaccharide… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.